Stay updated with breaking news from Robin Knifsend. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
From trade relations to industry reputations, five biopharmaceutical executives share their thoughts on top-of-mind topics as we ready for 2022 and...
Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Mardi Dier to its board of directors, Robin Knifsend as senior vice president of finance and operations and Antoni Ribas, M.D., Ph.D., to its scientific advisory board.
Published: Jun 03, 2021 By Alex Keown 180 Life Sciences -- Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Of...